Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...